Luminex (Luminex) Total Current Assets : $481.8 Mil (As of Mar. 2021)

View and export this data going back to 2000. Start your Free Trial

What is Luminex Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Luminex's total current assets for the quarter that ended in Mar. 2021 was $481.8 Mil.

Luminex Total Current Assets Historical Data

The historical data trend for Luminex's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Luminex Total Current Assets Chart

Luminex Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Total Current Assets

Get a 7-Day Free Trial

173.74

224.64

202.74

202.47

509.03

Luminex Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
Total Current Assets	Get a 7-Day Free Trial															196.51	454.95	491.45	509.03	481.79

Luminex Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Luminex's Total Current Assets for the fiscal year that ended in Dec. 2020 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	309.407	+	66.963	+	123.134	+	9.527
	=	509.0

Luminex's Total Current Assets for the quarter that ended in Mar. 2021 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	271.56	+	69.051	+	132.089	+	9.085
	=	481.8

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Luminex (NAS:LMNX) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Luminex's Liquidation Value for the quarter that ended in Mar. 2021 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	271.56	-	330.984	+	0.75 * 69.051	+	0.5 * 132.089
=	58.4

Luminex Total Current Assets Related Terms

Thank you for viewing the detailed overview of Luminex's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Luminex (Luminex) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Luminex Corp (NAS:LMNX) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

12212 Technology Boulevard, Suite 130, Austin, TX, USA, 78727

Website

https://www.luminexcorp.com

Luminex Corp develops, manufactures, and sells proprietary biological testing technologies and products to testing laboratories. It primarily serves the life sciences industries by selling products used by laboratory professionals and clinical laboratories in performing diagnostics, drug research and discovery, and clinical tests on patients. Luminex's market segments mainly include Infectious disease, Personalized medicine, and Human genetics. It offers various solutions in diverse markets, including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, and food safety. The vast majority of the company's revenue is earned in the United States. The products offered are xMAP Products, ARIES Products and VERIGENE Products, among others.

Executives

Harriss T Currie	officer: SVP, Finance & CFO	12212 TECHNOLOGY BOULEVARD AUSTIN TX 78727
Todd C. Bennett	officer: SVP, Global Sales & Cust Ops	12212 TECHNOLOGY BLVD. AUSTIN TX 78727
Stephen L. Eck	director	12212 TECHNOLOGY BLVD., AUSTIN TX 78727
Edward A Ogunro	director
Eric Shapiro	officer: SR VP, GLOBAL MARKETING	12212 TECHNOLOGY BLVD. AUSTIN TX 78727
Nachum Shamir	director, officer: President & CEO	12212 TECHNOLOGY BLVD, AUSTIN TX 78727
Rew Richard W. Ii	officer: SVP, Gen Counsel & Corp Secy	7000 WEST WILLIAM CANNON, BUILDING ONE, AUSTIN TX 78735
Nancy Fairchild	officer: SVP, Human Resources	12212 TECHNOLOGY BLVD. AUSTIN TX 78727
G Walter Lowenbaum	director	C/O 3D SYSTEMS CORPORATION, 333 THREE D SYSTEMS CIRCLE, ROCK HILL SC 29730
Randall Myers	officer: SVP, Global Mfg and Quality	12212 TECHNOLOGY BOULEVARD AUSTIN TX 78727
Charles J. Collins	officer: SR VP, R&D - US	12212 TECHNOLOGY BLVD. AUSTIN TX 78727
Dijuana K Lewis	director	120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Jim D Kever	director	C/O 3D SYSTEMS, 26081 AVENUE HALL, VALENCIA CA 91355
Thomas W Erickson	director	OMEGA HEALTHCARE INVESTORS INC, 900 VICTORS WAY STE. 350, AMM ARBER MI 48108
Kenneth A Samet	director	800 KING FARM BOULEVARD, 4TH FLOOR, ROCKVILLE MD 20850